MXPA05012305A - Composiciones y metodos para el tratamiento de lesiones del snc. - Google Patents

Composiciones y metodos para el tratamiento de lesiones del snc.

Info

Publication number
MXPA05012305A
MXPA05012305A MXPA05012305A MXPA05012305A MXPA05012305A MX PA05012305 A MXPA05012305 A MX PA05012305A MX PA05012305 A MXPA05012305 A MX PA05012305A MX PA05012305 A MXPA05012305 A MX PA05012305A MX PA05012305 A MXPA05012305 A MX PA05012305A
Authority
MX
Mexico
Prior art keywords
injury
functions
compositions
treatment
methods
Prior art date
Application number
MXPA05012305A
Other languages
English (en)
Inventor
Andrew R Bligth
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of MXPA05012305A publication Critical patent/MXPA05012305A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Lubricants (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a un metodo para mejorar la recuperacion funcional seguida a una lesion de contusion en el sistema nervioso central. El metodo incluye administrar una cantidad efectiva terapeuticamente de enzima de degradacion de glicosaminoglican. La enzima de degradacion de glicosaminoglican puede ser enzimas de degradacion de sulfato de dermatan o sulfato de condroitina. La lesion por contusion del sistema nervioso central puede incluir una lesion cerebral traumatica o una lesion de la medula espinal. La recuperacion funcional puede incluir funciones autonomas, funciones sensoriales, funciones motoras o similares.
MXPA05012305A 2003-05-16 2004-05-17 Composiciones y metodos para el tratamiento de lesiones del snc. MXPA05012305A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47123603P 2003-05-16 2003-05-16
PCT/US2004/015253 WO2004103299A2 (en) 2003-05-16 2004-05-17 Compositions and methods for the treatment of cns injuries

Publications (1)

Publication Number Publication Date
MXPA05012305A true MXPA05012305A (es) 2006-04-18

Family

ID=33476545

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05012305A MXPA05012305A (es) 2003-05-16 2004-05-17 Composiciones y metodos para el tratamiento de lesiones del snc.

Country Status (10)

Country Link
US (3) US20080025963A1 (es)
EP (2) EP2353606B1 (es)
JP (2) JP4754492B2 (es)
AT (1) ATE524067T1 (es)
AU (1) AU2004241088B2 (es)
CA (1) CA2525804C (es)
ES (2) ES2373039T3 (es)
MX (1) MXPA05012305A (es)
PL (1) PL1631234T3 (es)
WO (1) WO2004103299A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60336341D1 (de) 2002-05-04 2011-04-21 Acorda Therapeutics Inc Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
ES2887949T3 (es) 2003-05-16 2021-12-29 Acorda Therapeutics Inc Mutantes degradantes de proteoglicanos para el tratamiento del SNC
CA2566731C (en) * 2004-05-18 2012-07-24 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
JP2006232754A (ja) * 2005-02-25 2006-09-07 Gi Biopolis:Kk 消化管粘膜切除後の消化管潰瘍治癒促進用スプレー剤
CA2623635C (en) 2005-09-26 2013-04-02 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
JP2010504359A (ja) 2006-09-20 2010-02-12 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 局部麻酔および／または疼痛緩和のための、揮発性麻酔剤を送達するための方法
TW200817015A (en) * 2006-10-06 2008-04-16 Hen-Rich Cheng A method for promoting axonal re-growth and behavior recovery in spinal cord injury
AU2014200000B2 (en) * 2006-10-10 2016-04-21 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
US7722864B2 (en) * 2006-10-10 2010-05-25 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
AU2016206267B2 (en) * 2006-10-10 2018-07-05 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
WO2008149428A1 (ja) * 2007-06-05 2008-12-11 Glycoscience Laboratories, Inc. 自己免疫疾患、炎症及び神経疾患の治療剤及び予防剤
US20110059508A1 (en) 2007-06-29 2011-03-10 National University Corporation Nagoya University Improving agent for dysfunction due to neuropathy and rho kinase activation inhibitor
US8198083B1 (en) 2007-10-31 2012-06-12 William Gunter Loudon Organotypic slices of the central nervous system
CA2712731C (en) 2008-01-22 2016-05-03 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
EP2286828B1 (en) * 2008-04-14 2016-05-18 National University Corporation Nagoya University Improving agent for neuropathic pain
EP2153844A1 (en) * 2008-08-14 2010-02-17 HAUBECK, Hans-Dieter Human hyaluronidases for axonal regrowth
WO2012136768A1 (en) 2011-04-08 2012-10-11 Hans-Dieter Haubeck Use of mutants of human hyaluronidase ph-20 with increased chondroitinase activity for axonal regrowth
ES2771448T3 (es) 2013-06-18 2020-07-06 Univ Helsinki La protamina en el tratamiento de las lesiones neuronales
CN108795918A (zh) * 2018-07-18 2018-11-13 北京电子科技职业学院 一种外切型硫酸软骨素酶abc及其制备方法与应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270194A (en) * 1989-08-31 1993-12-14 Instrumentation Laboratory Spa Stabilized glucose oxidase from Aspergillus Niger
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US5679650A (en) * 1993-11-24 1997-10-21 Fukunaga; Atsuo F. Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
US5262522A (en) * 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5496718A (en) * 1992-06-26 1996-03-05 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Chondroitinase ABC isolated from proteus vulgaris ATCC 6896
US7008783B1 (en) * 1992-09-22 2006-03-07 Maruha Corporation Gene encoding chondroitinase ABC and uses therefor
US5578480A (en) * 1993-04-23 1996-11-26 American Cyanamid Company Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris
US6248562B1 (en) * 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
US5498536A (en) * 1994-04-22 1996-03-12 American Cyanamid Company Chondroitinase II from Proteus vulgaris
US5997863A (en) 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes
US6093563A (en) 1994-07-08 2000-07-25 Ibex Technologies R And D, Inc. Chondroitin lyase enzymes
US6326166B1 (en) * 1995-12-29 2001-12-04 Massachusetts Institute Of Technology Chimeric DNA-binding proteins
US5792743A (en) * 1995-04-19 1998-08-11 Acorda Therapeutics Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule
US6313265B1 (en) 1995-07-24 2001-11-06 The Scripps Research Institute Neurite outgrowth-promoting polypeptides containing fibronectin type III repeats and methods of use
US5869301A (en) * 1995-11-02 1999-02-09 Lockhead Martin Energy Research Corporation Method for the production of dicarboxylic acids
CA2285940A1 (en) * 1997-04-11 1998-10-22 K. Ramakrishnan Bhaskar Use of chondroitinase in the manufacture of a medicament in the treatment and prevention of mucoid secretions
DE69829605T2 (de) * 1997-05-02 2006-02-09 Seikagaku Corp. Chondroitinase enthaltende Zusammensetzungen
DE69808402T2 (de) * 1997-08-22 2003-07-03 Seikagaku Kogyo Co Ltd Arzneimittel zur Behandlung von durch Hernie gestörter intervertebraler Bandscheibe
US6153187A (en) * 1997-09-02 2000-11-28 Insight Strategy & Marketing Ltd. Use of glycosaminoglycans degrading enzymes for management of airway associated diseases
WO1999046368A2 (en) * 1998-03-13 1999-09-16 Biomarin Pharmaceuticals Carbohydrate-modifying enzymes for burn and wound debridement and methods for treatment
US6171575B1 (en) * 1998-04-06 2001-01-09 Shinichi Okuyama Method of radioisotopic assessment of the integrity and function of the nose-brain barrier
WO2000012726A2 (en) * 1998-08-27 2000-03-09 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
DE69927512T2 (de) * 1998-10-06 2006-07-06 Stryker Corp., Kalamazoo Verwendung von op-1 zur herstellung einer pharmazeutischen zusammensetzung zur reparatur von nicht-gelenksknorpeldefekten eines säugers
US5932563A (en) * 1998-10-23 1999-08-03 Ohio State Research Foundation Methods for treating spinal cord injury
EP1263459A2 (en) * 1999-12-02 2002-12-11 Ibex Technologies, Inc. Attenuation of fibroblast proliferation
WO2003000901A2 (en) * 2001-06-26 2003-01-03 Decode Genetics Ehf. Nucleic acids encoding protein kinases
JP4749667B2 (ja) * 2001-08-13 2011-08-17 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 神経組織の修復を促進するための材料および方法
GB0205022D0 (en) * 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
DE60336341D1 (de) * 2002-05-04 2011-04-21 Acorda Therapeutics Inc Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
WO2003102160A2 (en) * 2002-06-03 2003-12-11 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase b
US7163545B2 (en) * 2002-07-29 2007-01-16 Mayo Foundation For Medical Education And Research Spinal cord surgical implant
US7074581B2 (en) * 2002-08-09 2006-07-11 Sysmex Corporation Reagent for assaying lipid
AU2003264033A1 (en) * 2002-08-10 2004-02-25 Biogen Idec Ma Inc. Nogo receptor antagonists
EP1530643B1 (en) * 2002-08-15 2011-05-04 Acorda Therapeutics, Inc. Chimeric protein
US7199110B2 (en) * 2002-12-30 2007-04-03 Purdue Research Foundation Method of treatment for spinal cord injury
ES2887949T3 (es) * 2003-05-16 2021-12-29 Acorda Therapeutics Inc Mutantes degradantes de proteoglicanos para el tratamiento del SNC
US7959914B2 (en) * 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
EP1737954A2 (en) * 2004-03-10 2007-01-03 The Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
CA2623635C (en) * 2005-09-26 2013-04-02 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants

Also Published As

Publication number Publication date
EP1631234B1 (en) 2011-09-14
JP4754492B2 (ja) 2011-08-24
AU2004241088A1 (en) 2004-12-02
US20140248253A1 (en) 2014-09-04
EP1631234A4 (en) 2008-11-19
US20200016247A1 (en) 2020-01-16
JP2011126880A (ja) 2011-06-30
EP2353606B1 (en) 2013-04-17
ATE524067T1 (de) 2011-09-15
AU2004241088B2 (en) 2010-08-05
CA2525804C (en) 2017-04-25
WO2004103299A8 (en) 2005-03-31
US20080025963A1 (en) 2008-01-31
EP1631234A2 (en) 2006-03-08
JP5432113B2 (ja) 2014-03-05
CA2525804A1 (en) 2004-12-02
ES2420510T3 (es) 2013-08-23
EP2353606A2 (en) 2011-08-10
JP2007520447A (ja) 2007-07-26
WO2004103299A3 (en) 2008-01-24
EP2353606A3 (en) 2011-08-31
ES2373039T3 (es) 2012-01-30
WO2004103299A2 (en) 2004-12-02
PL1631234T3 (pl) 2012-02-29

Similar Documents

Publication Publication Date Title
MXPA05012305A (es) Composiciones y metodos para el tratamiento de lesiones del snc.
DE60335244D1 (de) Behandlung von verletzungen des zentralen nervensystems
HK1076713A1 (en) Immunomodulatory compounds and methods of use thereof
UA85055C2 (ru) Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
GB0300789D0 (en) Stimulation method for the sphenopalatine ganglia,sphenopalatine nerve,or vidian nerve for treatment of medical conditions
WO2004060146A3 (en) Method of treatment for central nervous system injury
WO2004028624A3 (en) Nerve stimulation for treating spasticity, tremor, muscle weakness, and other motor disorders
MX348062B (es) Mutantes que degradan proteoglicanos para tratamiento del snc.
WO2004082624A3 (en) Modafinil-based neurorehabilitation of impaired neurological function associated with injury
BG104466A (en) Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration
MX351062B (es) Proteinas de fusion para el tratamiento del snc.
WO2004028468A3 (en) Methods and compositions for treatment of neurological disorder
AU2003304173A8 (en) Compositions and methods for promoting neuronal outgrowth
MX349462B (es) Composiciones y metodos para el tratamiento de lesiones del snc.
BG103252A (en) The use of benzopyranols for the treatment of neurological disorders
IL130586A0 (en) IL6RIL6 chimera for the treatment of demyelinating diseases
EP1546377A4 (en) METHODS AND COMPOSITIONS FOR TREATING PAIN AND PAIN DISORDERS USING MOLECULES 9949, 14230, 760, 62553, 41897, 47174, 33408, 10002, 16209, 314, 636, 27410, 33260, 619, 15985, 69112, 2158, 224, 615, 44373, 95431, 22245, 2387, 16658, 55054, 9569 OR 13424
HUP0002318A1 (hu) Eljárás idegregenerálódás serkentésére
AUPP379698A0 (en) Using ngali nut oil to treat/relieve the pain of arthritis and other similar conditions
WO2004071419A3 (en) Methods and compositions for modulating glutamate transport activity in the nervous system
PL373391A1 (en) Aldosterone blocker therapy to prevent or treat inflammation-related disorders
CA2481263A1 (en) Use of pyrimidine nucleotides for the treatment of affections of the peripheral nervous system
WO2004058154A3 (en) Method of identifying therapeutic agents
WO2004112806A8 (en) Composition for treating or preventing neural disorders
WO2004112721A3 (en) Prevention or treatment of deficits that arise in connection with diseases of, or injuries to, the nervous system

Legal Events

Date Code Title Description
FG Grant or registration